Biocartis Submits Idylla Platform With Janssen Flu, RSV Test to FDA

Dec 22, 2016

|

NEW YORK (GenomeWeb) – Biocartis announced today that it has submitted its Idylla molecular diagnostics platform to the US Food and Drug Administration for 510(k) clearance, along with a respiratory panel from partner Janssen Diagnostics to detect influenza and respiratory syncytial virus using the Idylla platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocartis Submits Idylla Platform With Janssen Flu, RSV Test to FDA

To read the full story....

Breaking News

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

New York City Opening Dedicated COVID-19 Testing Laboratory

Scipher Medicine Taps Ambry Genetics to Scale Up TNF Inhibitor Response Test

FDA Proposes Reclassification of Cytomegalovirus Quantitative Tests

AACC Calls on Congress to Fund Clinical Lab Training Programs

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

What's Popular?

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Novacyt H1 Revenues Surge on Coronavirus Testing Product Sales

Eurobio Gets CE Mark for Multiplexed SARS-CoV-2, Influenza A/B, RSV Test

Sponsorships